# US 2010/0168382 A1 · Neuroplastin derived peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168382 A1
- Document ID: US20100168382A1
- Status: Published application
- Kind: A1
- Application number: 12/664,085
- Filed: 2008-06-06
- Published: 2010-07-01
- Earliest claimed: 2007-06-12
- Inventors: Vladimir Berezin
- Web page: https://patentgrep.com/patent/US20100168382A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to peptides derived from neuroplastin which are capable of inducing neurite outgrowth by modulating intracellular calcium concentration and activity of intracellular signalling molecules such as Akt, Erk1/2 and CREB through binding and/or modulation of receptor tyrosine kinases including but not limited to Fibroblast Growth Factor receptors (FGFRs). The peptides are derived from neuroplastin or fragments thereof. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein neuroplastin and/or receptor tyrosine kinases, including but not limited to FGFRs, play a prominent role.

## Claims

### Claim 1

A pharmaceutical composition comprising a peptide comprising an amino acid sequence of neuroplastin (SEQ ID NO:1) or a fragment or variant thereof, said peptide being capable of modulating the activity of receptor tyrosine kinases.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said peptide or variant is capable of modulating the activity of FGFRs.

### Claim 3

The pharmaceutical composition according to any of the preceding claims, wherein said peptide comprises one or more of the following amino acid sequences:
TKLTGDAFEL
SEQ ID NO: 2
DVVGSPTPEIQ
SEQ ID NO: 3
NRAESFRQLWDGAR
SEQ ID NO: 4
RRVTVNTAYGSNG
SEQ ID NO: 5
DPKRNDLRQNPSITWIR
SEQ ID NO: 6
RIVTSEEVIIRDS
SEQ ID NO: 7
NLTSSSHTLMYS
SEQ ID NO: 8
TKNGVELTATRKNA
SEQ ID NO: 9
KNASNMEYRINKP
SEQ ID NO: 10
NKPRAEDSGE
SEQ ID NO: 11
VYHFVSAPKANAT
SEQ ID NO: 12
INKENYTELN
SEQ ID NO: 13
or a fragment, or variant thereof.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, wherein said peptide fragment is a variant fragment, wherein said variant sequence is at least 75% identical to said fragment, such as wherein the variant sequence is at least 80% identical to said fragment, such as wherein the variant sequence is at least 90% identical to said fragment.

### Claim 5 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence TKLTGDAFEL (SEQ ID NO:2).

### Claim 6 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence DVVGSPTPEIQ (SEQ ID NO:3).

### Claim 7 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence NRAESFRQLWDGAR (SEQ ID NO:4).

### Claim 8 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence RRVTVNTAYGSNG (SEQ ID NO:5).

### Claim 9 (depends on 1, 2, 3)

The pharmaceutical composition according any of claims 1-3, wherein the peptide comprises the amino acid sequence DPKRNDLRQNPSITWIR (SEQ ID NO:6).

### Claim 10 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence RIVTSEEVIIRDS (SEQ ID NO:7).

### Claim 11 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence NLTSSSHTLMYS (SEQ ID NO:8).

### Claim 12 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence TKNGVELTATRKNA (SEQ ID NO:9).

### Claim 13 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence KNASNMEYRINKP (SEQ ID NO:10).

### Claim 14 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence NKPRAEDSGE (SEQ ID NO:11).

### Claim 15 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence VYHFVSAPKANAT (SEQ ID NO:12).

### Claim 16 (depends on 1, 2, 3)

The pharmaceutical composition according to any of claims 1-3, wherein the peptide comprises the amino acid sequence INKENYTELN (SEQ ID NO:13).

### Claim 17

The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of modulating Akt activity.

### Claim 18

The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of modulating Erk 1/2 activity.

### Claim 19

The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of modulating CREB activation.

### Claim 20

The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of stimulating neurite outgrowth.

### Claim 21

The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of stimulating cell survival.

### Claim 22

The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of stimulating synaptic plasticity.

### Claim 23

The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of stimulation learning and/or memory.

### Claim 24

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of diseases or conditions wherein modulation of receptor tyrosine kinases is essential.

### Claim 25

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of diseases or conditions wherein modulation of FGFRs is essential.

### Claim 26

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of diseases or conditions of the central or peripheral nervous system.

### Claim 27

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of a disease or condition wherein stimulation of neural cell differentiation, neural cell survival, neurogenesis, stem cell proliferation, stem cell differentiation, and/or learning and memory is beneficial for recovery from said disease or condition.

### Claim 28

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, multiinfarct dementia, multiple sclerosis, nerve degeneration associated with diabetes mellitus, neuro-muscular degeneration, schizophrenia, mood disorders, manic depressive disorders, Alzheimer's disease, Parkinson's disease, or Huntington's disease.

### Claim 29

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, or for the treatment of diseases or degenerative conditions of the gonads, pancreas or kidney.

### Claim 30

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of preventing cell death of heart muscle cells.

### Claim 31

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of stimulating revascularisation.

### Claim 32

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of promotion of wound healing.

### Claim 33

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of inhibiting angiogenesis.

### Claim 34

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of cancer.

### Claim 35

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of stimulation of the ability to learn and/or of the short and/or long term memory.

### Claim 36

The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of modulating proliferation and/or differentiation and/or regeneration and/or morphological plasticity of cells.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A peptide being a variant or a fragment of neuroplastin (SEQ ID NO:1), wherein said variant or fragment is as defined in any of claims 1-16.

### Claim 38 (depends on 37)

The peptide according to claim 37, wherein said peptide is capable of modulating Akt activity.

### Claim 39 (depends on 37)

The peptide according to claim 37, wherein said peptide is capable of modulating Erk 1/2 activity.

### Claim 40 (depends on 37)

The peptide according to claim 37, wherein said peptide is capable of modulating CREB activation.

### Claim 41 (depends on 37)

The peptide according to claim 37, wherein said peptide is capable of stimulating neurite outgrowth.

### Claim 42 (depends on 37)

The peptide according to claim 37, wherein said peptide is capable of stimulating cell survival.

### Claim 43 (depends on 37)

The peptide according to claim 37, wherein said peptide is capable of stimulating synaptic plasticity.

### Claim 44 (depends on 37)

The peptide according to claim 37, wherein said peptide is capable of stimulation learning and/or memory.

### Claim 45 (depends on 37, 38, 39, 40, 41, 42, 43, 44)

The peptide as defined in any of claims 37-44 for use as a medicament.

### Claim 46 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The peptide as defined in any of claims 37-44 for the treatment of any of the conditions or diseases as defined in any of claims 24-36.

### Claim 47 (depends on 37)

Use of a peptide as defined in claim 37 for the production of an antibody.

### Claim 48

An antibody capable of binding to an epitope comprising a sequence corresponding to neuroplastin or a fragment thereof or a variant.

### Claim 49

An antibody capable of binding to an epitope comprising at least one of the following sequences:
TKLTGDAFEL
SEQ ID NO: 2
DVVGSPTPEIQ
SEQ ID NO: 3
NRAESFRQLWDGAR
SEQ ID NO: 4
RRVTVNTAYGSNG
SEQ ID NO: 5
DPKRNDLRQNPSITWIR
SEQ ID NO: 6
RIVTSEEVIIRDS
SEQ ID NO: 7
NLTSSSHTLMYS
SEQ ID NO: 8
TKNGVELTATRKNA
SEQ ID NO: 9
KNASNMEYRINKP
SEQ ID NO: 10
NKPRAEDSGE
SEQ ID NO: 11
VYHFVSAPKANAT
SEQ ID NO: 12
INKENYTELN.
SEQ ID NO: 13

### Claim 50 (depends on 41)

The antibody according to claim 41, wherein said antibody is capable of modulating biological activity mediated by receptor tyrosine kinase.

### Claim 51 (depends on 41)

The antibody according to claim 41, wherein said antibody is capable of modulating biological activity mediated by FGFRs.

### Claim 52 (depends on 41)

The antibody according to claim 41, wherein said antibody is capable of modulating biological activity mediated by Akt.

### Claim 53 (depends on 41)

The antibody according to claim 41, wherein said antibody is capable of modulating biological activity mediated by Erk 1/2.

### Claim 54 (depends on 41)

The antibody according to claim 41, wherein said antibody is capable of modulating biological activity mediated by CREB.

### Claim 55 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 41, 42, 43, 44, 45, 46, 47)

Use of an antibody according to claims 41-47 for the manufacture of a medicament for treatment of conditions or disesases as defined in claims 17-36.

### Claim 56 (depends on 41, 42, 43, 44, 45)

A pharmaceutical composition comprising an antibody according to any of claims 41-45.
